Ibanez Laura, Dube Umber, Davis Albert A, Fernandez Maria V, Budde John, Cooper Breanna, Diez-Fairen Monica, Ortega-Cubero Sara, Pastor Pau, Perlmutter Joel S, Cruchaga Carlos, Benitez Bruno A
Department of Psychiatry, Washington University, Saint Louis, MO, United States.
Department of Neurology, Washington University, Saint Louis, MO, United States.
Front Neurosci. 2018 Apr 10;12:230. doi: 10.3389/fnins.2018.00230. eCollection 2018.
The prevalence of dementia in Parkinson disease (PD) increases dramatically with advancing age, approaching 80% in patients who survive 20 years with the disease. Increasing evidence suggests clinical, pathological and genetic overlap between Alzheimer disease, dementia with Lewy bodies and frontotemporal dementia with PD. However, the contribution of the dementia-causing genes to PD risk, cognitive impairment and dementia in PD is not fully established. To assess the contribution of coding variants in Mendelian dementia-causing genes on the risk of developing PD and the effect on cognitive performance of PD patients. We analyzed the coding regions of the amyloid-beta precursor protein (), Presenilin 1 and 2 (), and Granulin () genes from 1,374 PD cases and 973 controls using pooled-DNA targeted sequence, human exome-chip and whole-exome sequencing (WES) data by single variant and gene base (SKAT-O and burden tests) analyses. Global cognitive function was assessed using the Mini-Mental State Examination (MMSE) or the Montreal Cognitive Assessment (MoCA). The effect of coding variants in dementia-causing genes on cognitive performance was tested by multiple regression analysis adjusting for gender, disease duration, age at dementia assessment, study site and carrier status. Known AD pathogenic mutations in the (p.A79V) and (p.V148I) genes were found in 0.3% of all PD patients. There was a significant burden of rare, likely damaging variants in the and genes in PD patients when compared with frequencies in the European population from the ExAC database. Multiple regression analysis revealed that PD patients carrying rare variants in the , and genes exhibit lower cognitive tests scores than non-carrier PD patients ( = 2.0 × 10), independent of age at PD diagnosis, age at evaluation, status or recruitment site. Pathogenic mutations in the Alzheimer disease-causing genes ( and are found in sporadic PD patients. PD patients with cognitive decline carry rare variants in dementia-causing genes. Variants in genes causing Mendelian neurodegenerative diseases exhibit pleiotropic effects.
帕金森病(PD)中痴呆的患病率随年龄增长而急剧上升,在患该疾病20年的存活患者中接近80%。越来越多的证据表明,阿尔茨海默病、路易体痴呆和伴有帕金森病的额颞叶痴呆之间存在临床、病理和基因重叠。然而,导致痴呆的基因对帕金森病风险、认知障碍和帕金森病痴呆的影响尚未完全明确。为了评估孟德尔致痴呆基因中的编码变异对帕金森病发病风险的影响以及对帕金森病患者认知表现的作用。我们使用混合DNA靶向序列、人类外显子芯片和全外显子测序(WES)数据,通过单变异和基因分型(SKAT - O和负荷检验)分析,对1374例帕金森病病例和973例对照的淀粉样前体蛋白()、早老素1和2()以及颗粒蛋白()基因的编码区进行了分析。使用简易精神状态检查表(MMSE)或蒙特利尔认知评估量表(MoCA)评估整体认知功能。通过对性别、疾病病程、痴呆评估时的年龄、研究地点和携带状态进行校正的多元回归分析,检验致痴呆基因中的编码变异对认知表现的影响。在所有帕金森病患者中,0.3%的患者存在(p.A79V)和(p.V148I)基因中已知的阿尔茨海默病致病突变。与ExAC数据库中欧洲人群的频率相比,帕金森病患者中、基因存在显著的罕见且可能有害的变异负荷。多元回归分析显示,携带、和基因罕见变异的帕金森病患者的认知测试得分低于非携带者帕金森病患者(= 2.0×10),与帕金森病诊断时的年龄、评估时的年龄、状态或招募地点无关。散发性帕金森病患者中存在阿尔茨海默病致病基因(和)的致病突变。认知功能下降的帕金森病患者在致痴呆基因中携带罕见变异。导致孟德尔神经退行性疾病的基因变异具有多效性。